IP, M&A, life sciences and competition partners advised on deal that brings together brands such as ‘Huggies’ and ‘Kleenex’ ...

CEO Alex Karp used the company's earnings call to dismiss his critics, saying, "Enjoy, get some popcorn, they're crying." ...

Asian shares have retreated despite the big lift in overseas markets from optimism over AI technology. Shares declined ...

Kimberly-Clark plans a $48.7B Kenvue acquisition to drive growth and synergies. Learn the deal's risks, impacts, and KMB's ...

Despite a headline beat and decent revenue forecast, the poor reaction to the update from AI and data analytics darling ...

In this piece, we will look at the stocks Jim Cramer discussed.

Consumer giant Kimberly-Clark has agreed to buy Kenvue, the parent company of embattled brand Tylenol, for nearly $49 billion. But what does this mean for consumers and shareholders?

Under the agreement, each Kenvue Inc. (NYSE:KVUE) shareholder would receive $3.5 per share in cash as well as 0.14625 ...

Kimberly-Clark is buying Tylenol maker Kenvue in a cash and stock deal worth about $48.7 billion, creating a huge consumer ...